NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
Alexion Pharmaceuticals, Inc.
State University of New York at Buffalo
Johns Hopkins University
Abide Therapeutics
University of California, San Francisco